---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-067940"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:28:02.984938+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Iovance appoints Corleen Roche as CFO effective August 6, 2025

## Summary
- Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.
- Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.
- Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.
- Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting.

## SEC filing metadata
- accession: 0001104659-25-067940
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/0001104659-25-067940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/tm2520947d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-067940
- JSON: https://secwatch.observer/filing/0001104659-25-067940.json
- Plain text: https://secwatch.observer/filing/0001104659-25-067940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.